SMEJKAL, Petr, Petr BRABEC, Miloslava MATÝŠKOVÁ, Alena BULIKOVÁ, Marie ŠLECHTOVÁ, Jarmila KISSOVÁ, Gabriela CHLUPOVÁ, Jan MUŽÍK and Miroslav PENKA. FEIBA(R) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia. 2009, vol. 15, No 3, p. 743-751. ISSN 1351-8216.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name FEIBA(R) in treatment of acute bleeding episodes in patients with haemophilia A and factor VIII inhibitors: a retrospective survey in regional haemophilia centre
Name in Czech FEIBA(R) v léčbě akutního krvácení u pacientů s hemofilií A a inhibitorem faktoru VIII: retrospektivní studie regionálního centra
Authors SMEJKAL, Petr (203 Czech Republic, guarantor), Petr BRABEC (203 Czech Republic), Miloslava MATÝŠKOVÁ (203 Czech Republic), Alena BULIKOVÁ (203 Czech Republic), Marie ŠLECHTOVÁ (203 Czech Republic), Jarmila KISSOVÁ (203 Czech Republic), Gabriela CHLUPOVÁ (203 Czech Republic), Jan MUŽÍK (203 Czech Republic) and Miroslav PENKA (203 Czech Republic).
Edition Haemophilia, 2009, 1351-8216.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.505
RIV identification code RIV/00216224:14110/09:00036074
Organization unit Faculty of Medicine
UT WoS 000265409600013
Keywords in English haemophilia; bleeding; FEIBA
Tags bleeding, FEIBA, haemophilia
Changed by Changed by: RNDr. Jan Mužík, Ph.D., učo 1574. Changed: 1/4/2010 14:42.
Abstract
FEIBA(R) is used to achieve haemostasis in haemophiliacs with inhibitor. The aim of this study was to evaluate efficacy and consumption of the product in treatment of haemorrhages in haemophiliacs with factor VIII inhibitor, and determine factors that can influence the results of treatment. We used data from our haemophilia centre from years 2000-2008. Six haemophiliacs with factor VIII inhibitor were treated on demand with FEIBA(R) for 61 bleeding episodes (45 haemarthroses, six muscle bleeds, six other sites bleeds and four multiple sites bleeds).
Abstract (in Czech)
FEIBA(R) is used to achieve haemostasis in haemophiliacs with inhibitor. The aim of this study was to evaluate efficacy and consumption of the product in treatment of haemorrhages in haemophiliacs with factor VIII inhibitor, and determine factors that can influence the results of treatment. We used data from our haemophilia centre from years 2000-2008. Six haemophiliacs with factor VIII inhibitor were treated on demand with FEIBA(R) for 61 bleeding episodes (45 haemarthroses, six muscle bleeds, six other sites bleeds and four multiple sites bleeds).
PrintDisplayed: 28/5/2024 07:23